Avalanche Biotechnologies Inc. touched off a Wall Street landslide by disclosing phase IIa results with gene therapy AVA-101 for wet age-related macular degeneration (AMD) that showed the trial's 12-month primary endpoint was met, based on ophthalmic and systemic safety.